nct_id: NCT05304377
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-03-31'
study_start_date: '2022-05-22'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: ELVN-001'
long_title: A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
last_updated: '2025-11-19'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Enliven Therapeutics
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 200
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* BCR-ABL1 positive CML in chronic phase, with or without T315I mutation.'
- '* US: The patient has failed or is intolerant to at least one prior second-generation
  tyrosine kinase inhibitor (TKI) or asciminib. Rest of World: The patient has failed,
  is intolerant to, or not a candidate for, available therapies known to be active
  for treatment of their CML (country-specific criteria may vary).'
- '* ECOG performance status of 0 to 2.'
- '* Adequate hematologic, hepatic and renal function.'
- "* Prior bone marrow transplant allowed if \u2265 6 months prior to the first dose\
  \ of ELVN-001."
- 'Exclude - Exclusion Criteria:'
- Exclude - * Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives,
  whichever is longer.
- Exclude - * History of acute tyrosine kinase inhibitor (TKI)-related pancreatitis
  within 6 months of study entry. Active chronic pancreatitis, or pancreatic disease
  due to any cause.
- Exclude - * QTc \>470 ms.
short_title: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Enliven Therapeutics
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to evaluate the safety, tolerability and determine
  the recommended dose for further clinical evaluation of ELVN-001 in patients with
  chronic myeloid leukemia with and without T315I mutations in patients who are relapsed,
  refractory or intolerant to TKIs.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Phase 1a Dose Escalation
      arm_internal_id: 0
      arm_description: ELVN-001 administered in 3+3 dose escalation
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: ELVN-001'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Phase 1b Dose Expansion (non-T315I)
      arm_internal_id: 1
      arm_description: ELVN-001 administered at one or more recommended dose(s) for
        expansion in CML without T315I mutations
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: ELVN-001'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Phase 1b expansion (T315I)
      arm_internal_id: 2
      arm_description: ELVN-001 administered at the recommended dose for expansion
        for CML with T315I mutation
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: ELVN-001'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Early Stage
        - Refractory
        oncotree_primary_diagnosis: Myeloid Neoplasm
